Skip to main content
Heritage Bio Labs · Research use only
Heritage Bio Labs

Research Library

PT-141 research

6 articles to explore, with links to 5 original sources.

About PT-141

PT-141, also known as bremelanotide, is a cyclic peptide used in melanocortin receptor research.

Understand the science

Explore study findings

Check methods and identity

  • What the Current US Bremelanotide Label Covers

    PT-141 is a name used for bremelanotide, a cyclic peptide that activates melanocortin receptors. A defined prescription product, Vyleesi, is FDA approved for a specific condition. The October 2026 US prescribing information explains which people and circumstances were included in that indication.

    1 source (2026)

  • How Two Phase 3 Trials Measured Desire and Distress Separately

    Bremelanotide, also called PT-141, is a melanocortin receptor agonist. Two older phase 3 studies directly tested the prescription candidate in premenopausal women with hypoactive sexual desire disorder. The 2026 label still summarizes these pivotal comparisons.

    2 sources (2019, 2026)

  • What the 2026 Bremelanotide Label Reports About Safety

    PT-141 is also known as bremelanotide. The October 2026 US label for the approved product, Vyleesi, records safety findings from its clinical evaluation. Those findings apply to that specific drug product and the settings in which it was studied.

    1 source (2026)

Interpret the evidence

Articles from the Heritage Bio Labs research series, with links to the original sources. For research use only; not medical advice.